RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Tarun Mandal to Nanoparticles

This is a "connection" page, showing publications Tarun Mandal has written about Nanoparticles.
Connection Strength

3.156
  1. Graves RA, Ledet GA, Nation CA, Pramar YV, Bostanian LA, Mandal TK. Effect of squalane on mebendazole-loaded Compritol? nanoparticles. J Biomater Sci Polym Ed. 2015; 26(13):868-80.
    View in: PubMed
    Score: 0.376
  2. Graves RA, Ledet GA, Glotser EY, Mitchner DM, Bostanian LA, Mandal TK. Formulation and evaluation of biodegradable nanoparticles for the oral delivery of fenretinide. Eur J Pharm Sci. 2015 Aug 30; 76:1-9.
    View in: PubMed
    Score: 0.371
  3. Ledet G, Pamujula S, Walker V, Simon S, Graves R, Mandal TK. Development and in vitro evaluation of a nanoemulsion for transcutaneous delivery. Drug Dev Ind Pharm. 2014 Mar; 40(3):370-9.
    View in: PubMed
    Score: 0.322
  4. Kundu AK, Chandra PK, Hazari S, Ledet G, Pramar YV, Dash S, Mandal TK. Stability of lyophilized siRNA nanosome formulations. Int J Pharm. 2012 Feb 28; 423(2):525-34.
    View in: PubMed
    Score: 0.293
  5. Pamujula S, Hazari S, Bolden G, Graves RA, Chinta DD, Dash S, Kishore V, Mandal TK. Cellular delivery of PEGylated PLGA nanoparticles. J Pharm Pharmacol. 2012 Jan; 64(1):61-7.
    View in: PubMed
    Score: 0.292
  6. Kundu AK, Chandra PK, Hazari S, Pramar YV, Dash S, Mandal TK. Development and optimization of nanosomal formulations for siRNA delivery to the liver. Eur J Pharm Biopharm. 2012 Feb; 80(2):257-67.
    View in: PubMed
    Score: 0.292
  7. Pamujula S, Hazari S, Bolden G, Graves RA, Chinta DM, Dash S, Kishore V, Mandal TK. Preparation and in-vitro/in-vivo evaluation of surface-modified poly (lactide-co-glycolide) fluorescent nanoparticles. J Pharm Pharmacol. 2010 Apr; 62(4):422-9.
    View in: PubMed
    Score: 0.261
  8. Pamujula S, Kishore V, Rider B, Agrawal KC, Mandal TK. Radioprotection in mice following oral administration of WR-1065/PLGA nanoparticles. Int J Radiat Biol. 2008 Nov; 84(11):900-8.
    View in: PubMed
    Score: 0.236
  9. Praetorius NP, Mandal TK. Engineered nanoparticles in cancer therapy. Recent Pat Drug Deliv Formul. 2007; 1(1):37-51.
    View in: PubMed
    Score: 0.208
  10. Kundu AK, Iyer SV, Chandra S, Adhikari AS, Iwakuma T, Mandal TK. Novel siRNA formulation to effectively knockdown mutant p53 in osteosarcoma. PLoS One. 2017; 12(6):e0179168.
    View in: PubMed
    Score: 0.108
  11. Powell D, Chandra S, Dodson K, Shaheen F, Wiltz K, Ireland S, Syed M, Dash S, Wiese T, Mandal T, Kundu A. Aptamer-functionalized hybrid nanoparticle for the treatment of breast cancer. Eur J Pharm Biopharm. 2017 May; 114:108-118.
    View in: PubMed
    Score: 0.105
  12. Kumar R, Ledet G, Graves R, Datta D, Robinson S, Bansal GP, Mandal T, Kumar N. Potent Functional Immunogenicity of Plasmodium falciparum Transmission-Blocking Antigen (Pfs25) Delivered with Nanoemulsion and Porous Polymeric Nanoparticles. Pharm Res. 2015 Dec; 32(12):3827-36.
    View in: PubMed
    Score: 0.094
  13. Ledet GA, Graves RA, Glotser EY, Mandal TK, Bostanian LA. Preparation and in vitro evaluation of hydrophilic fenretinide nanoparticles. Int J Pharm. 2015 Feb 20; 479(2):329-37.
    View in: PubMed
    Score: 0.090
  14. Chandra PK, Kundu AK, Hazari S, Chandra S, Bao L, Ooms T, Morris GF, Wu T, Mandal TK, Dash S. Inhibition of hepatitis C virus replication by intracellular delivery of multiple siRNAs by nanosomes. Mol Ther. 2012 Sep; 20(9):1724-36.
    View in: PubMed
    Score: 0.076
  15. Chowdhury N, Chaudhry S, Hall N, Olverson G, Zhang QJ, Mandal T, Dash S, Kundu A. Targeted Delivery of Doxorubicin Liposomes for Her-2+ Breast Cancer Treatment. AAPS PharmSciTech. 2020 Jul 21; 21(6):202.
    View in: PubMed
    Score: 0.033
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support